[Complete response to durvalumab+tremelimumab as second-line therapy after atezolizumab+bevacizumab in peritoneal recurrence after liver resection: a case report].

A male patient in his 70s experienced peritoneal dissemination recurrence after resection for hepatocellular carcinoma. The disease progressed despite initial atezolizumab+bevacizumab combination therapy. Consequently, durvalumab+tremelimumab combination therapy was initiated. After one treatment course, the peritoneal disseminated lesions reduced in size, and the protein induced by vitamin K absence or antagonist-II (PIVKA-II) values remarkably decreased. After seven chemotherapy courses, the peritoneal disseminated lesions disappeared, and the PIVKA-II values decreased to normal levels. Peritoneal recurrence after liver resection is generally considered to have a poor prognosis. This case report describes the remarkable efficacy of a combination therapy with durvalumab+tremelimumab after atezolizumab+bevacizumab in advanced hepatocellular carcinoma.